GB201013989D0 - Biological materials and methods of using the same - Google Patents

Biological materials and methods of using the same

Info

Publication number
GB201013989D0
GB201013989D0 GBGB1013989.7A GB201013989A GB201013989D0 GB 201013989 D0 GB201013989 D0 GB 201013989D0 GB 201013989 A GB201013989 A GB 201013989A GB 201013989 D0 GB201013989 D0 GB 201013989D0
Authority
GB
United Kingdom
Prior art keywords
methods
same
biological materials
biological
materials
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1013989.7A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Southampton
Original Assignee
University of Southampton
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Southampton filed Critical University of Southampton
Priority to GBGB1013989.7A priority Critical patent/GB201013989D0/en
Publication of GB201013989D0 publication Critical patent/GB201013989D0/en
Priority to CA2808744A priority patent/CA2808744C/en
Priority to CN202110959481.9A priority patent/CN114099669A/zh
Priority to CN202110959353.4A priority patent/CN114099667B/zh
Priority to CN202110959355.3A priority patent/CN114099702B/zh
Priority to NO11760819A priority patent/NO2606068T3/no
Priority to SI201131366T priority patent/SI2606068T1/en
Priority to CN202110959354.9A priority patent/CN114099668B/zh
Priority to CN202110959352.XA priority patent/CN114099666B/zh
Priority to PL11760819T priority patent/PL2606068T3/pl
Priority to RU2013112345/10A priority patent/RU2013112345A/ru
Priority to PCT/GB2011/051572 priority patent/WO2012022985A1/en
Priority to DK11760819.0T priority patent/DK2606068T3/da
Priority to US13/817,744 priority patent/US10525129B2/en
Priority to KR1020137006990A priority patent/KR101948609B1/ko
Priority to EP11760819.0A priority patent/EP2606068B1/en
Priority to EP17184259.4A priority patent/EP3263602A1/en
Priority to CN202511469650.5A priority patent/CN121313820A/zh
Priority to RU2017143633A priority patent/RU2769949C2/ru
Priority to JP2013524483A priority patent/JP6215704B2/ja
Priority to PT117608190T priority patent/PT2606068T/pt
Priority to AU2011290503A priority patent/AU2011290503B2/en
Priority to HUE11760819A priority patent/HUE037478T2/hu
Priority to CN201710789909.3A priority patent/CN107670034B/zh
Priority to ES11760819.0T priority patent/ES2653685T3/es
Priority to CN201180040351XA priority patent/CN103080131A/zh
Priority to JP2016078639A priority patent/JP6421140B2/ja
Priority to US16/684,450 priority patent/US11623005B2/en
Priority to US17/359,496 priority patent/US20210346498A1/en
Priority to US18/177,050 priority patent/US12527866B2/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
GBGB1013989.7A 2010-08-20 2010-08-20 Biological materials and methods of using the same Ceased GB201013989D0 (en)

Priority Applications (30)

Application Number Priority Date Filing Date Title
GBGB1013989.7A GB201013989D0 (en) 2010-08-20 2010-08-20 Biological materials and methods of using the same
CN201180040351XA CN103080131A (zh) 2010-08-20 2011-08-19 FcγRIIB(CD32B)和CD20特异性抗体的组合应用
KR1020137006990A KR101948609B1 (ko) 2010-08-20 2011-08-19 Fc 감마 riib(cd32b) 및 cd20 - 특이적 항체의 복합 용도
EP11760819.0A EP2606068B1 (en) 2010-08-20 2011-08-19 COMBINED USE OF FC GAMMA RIIB (CD32B) AND CD19-, CD20- or CD40- SPECIFIC ANTIBODIES
CN202110959353.4A CN114099667B (zh) 2010-08-20 2011-08-19 FcγRIIB（CD32B）和CD20特异性抗体的组合应用
CN202110959355.3A CN114099702B (zh) 2010-08-20 2011-08-19 FcγRIIB（CD32B）和CD20特异性抗体的组合应用
NO11760819A NO2606068T3 (https=) 2010-08-20 2011-08-19
SI201131366T SI2606068T1 (en) 2010-08-20 2011-08-19 The combined use of FC gamma RIIb (CD32B) and CD19-, CD20- or CD40-specific antibodies
CN202110959354.9A CN114099668B (zh) 2010-08-20 2011-08-19 FcγRIIB（CD32B）和CD20特异性抗体的组合应用
CN202110959352.XA CN114099666B (zh) 2010-08-20 2011-08-19 FcγRIIB（CD32B）和CD20特异性抗体的组合应用
PL11760819T PL2606068T3 (pl) 2010-08-20 2011-08-19 SKOJARZONE ZASTOSOWANIE PRZECIWCIAŁ SPECYFICZNYCH WZGLĘDEM GAMMA RIIB (CD32B) I CD19, CD20 lub CD40
RU2013112345/10A RU2013112345A (ru) 2010-08-20 2011-08-19 Биологические материалы и способы их применения
PCT/GB2011/051572 WO2012022985A1 (en) 2010-08-20 2011-08-19 Combined use of fc gamma riib (cd32b) and cd20 - specific antibodies
DK11760819.0T DK2606068T3 (da) 2010-08-20 2011-08-19 Kombineret anvendelse af fc gamma riib (cd32b) og cd19-, cd20- eller cd40-specifikke antistoffer
US13/817,744 US10525129B2 (en) 2010-08-20 2011-08-19 Combined use of Fc gamma RIIb (CD32B) and CD20-specific antibodies
CA2808744A CA2808744C (en) 2010-08-20 2011-08-19 Combined use of fc gamma riib (cd32b) and cd20 specific antibodies
EP17184259.4A EP3263602A1 (en) 2010-08-20 2011-08-19 Combined use of fc gamma rub (cd32b) and cd20 specific antibodies
AU2011290503A AU2011290503B2 (en) 2010-08-20 2011-08-19 Combined use of Fc gamma RIIb (CD32B) and CD20 - specific antibodies
CN201710789909.3A CN107670034B (zh) 2010-08-20 2011-08-19 FcγRIIB(CD32B)和CD20特异性抗体的组合应用
RU2017143633A RU2769949C2 (ru) 2010-08-20 2011-08-19 Биологические материалы и способы их применения
JP2013524483A JP6215704B2 (ja) 2010-08-20 2011-08-19 Ｆｃガンマｒｉｉｂ（ｃｄ３２ｂ）特異的抗体およびｃｄ２０特異的抗体の併用使用
PT117608190T PT2606068T (pt) 2010-08-20 2011-08-19 Utilização combinada de fc gama riib (cd32b) e anticorpos específicos para cd19, cd20 ou cd40
CN202110959481.9A CN114099669A (zh) 2010-08-20 2011-08-19 FcγRIIB（CD32B）和CD20特异性抗体的组合应用
HUE11760819A HUE037478T2 (hu) 2010-08-20 2011-08-19 Fc gamma RIIB (CD32B) és CD19-, CD20- vagy CD40- specifikus ellenanyagok kombinált alkalmazása
CN202511469650.5A CN121313820A (zh) 2010-08-20 2011-08-19 FcγRIIB(CD32B)和CD20特异性抗体的组合应用
ES11760819.0T ES2653685T3 (es) 2010-08-20 2011-08-19 Uso combinado de Fc gamma RIIB (CD32B) y de anticuerpos específicos de CD19, CD20 o CD40
JP2016078639A JP6421140B2 (ja) 2010-08-20 2016-04-11 Ｆｃガンマｒｉｉｂ（ｃｄ３２ｂ）特異的抗体およびｃｄ２０特異的抗体の併用使用
US16/684,450 US11623005B2 (en) 2010-08-20 2019-11-14 Combined use of FcγRIIb (CD32B) and CD20 specific antibodies
US17/359,496 US20210346498A1 (en) 2010-08-20 2021-06-25 Combined use of fc gamma riib (cd32b) and cd20 specific antibodies
US18/177,050 US12527866B2 (en) 2010-08-20 2023-03-01 Combined use of Fc gamma RIIb (CD32B) and CD20 specific antibodies

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1013989.7A GB201013989D0 (en) 2010-08-20 2010-08-20 Biological materials and methods of using the same

Publications (1)

Publication Number Publication Date
GB201013989D0 true GB201013989D0 (en) 2010-10-06

Family

ID=42984443

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1013989.7A Ceased GB201013989D0 (en) 2010-08-20 2010-08-20 Biological materials and methods of using the same

Country Status (17)

Country Link
US (4) US10525129B2 (https=)
EP (2) EP2606068B1 (https=)
JP (2) JP6215704B2 (https=)
KR (1) KR101948609B1 (https=)
CN (8) CN114099669A (https=)
AU (1) AU2011290503B2 (https=)
CA (1) CA2808744C (https=)
DK (1) DK2606068T3 (https=)
ES (1) ES2653685T3 (https=)
GB (1) GB201013989D0 (https=)
HU (1) HUE037478T2 (https=)
NO (1) NO2606068T3 (https=)
PL (1) PL2606068T3 (https=)
PT (1) PT2606068T (https=)
RU (2) RU2769949C2 (https=)
SI (1) SI2606068T1 (https=)
WO (1) WO2012022985A1 (https=)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201013989D0 (en) 2010-08-20 2010-10-06 Univ Southampton Biological materials and methods of using the same
CN104812402A (zh) * 2012-11-29 2015-07-29 拜尔健康护理有限责任公司 针对活化蛋白C (aPC)的单克隆抗体
EP2740805B1 (en) * 2012-12-07 2019-02-20 SuppreMol GmbH Stratification and treatment of patients suffering from idiopathic thrombocytopenic purpura
RS60280B1 (sr) 2013-03-12 2020-06-30 Molecular Templates Inc Citotoksični proteini koji sadrže ciljane vezujuće regione za ćelije i regioni shiga toksina a podjedinice za selektivno ubijanje određenih vrsta ćelija
EP2833139A1 (en) * 2013-08-01 2015-02-04 SuppreMol GmbH In vitro method for determining the stability of compositions comprising soluble Fc gamma receptor(s)
CN111909278B (zh) 2014-01-27 2024-04-09 分子模板公司 Mhc i类表位递送多肽
US11142584B2 (en) 2014-03-11 2021-10-12 Molecular Templates, Inc. CD20-binding proteins comprising Shiga toxin A subunit effector regions for inducing cellular internalization and methods using same
GB2526139A (en) 2014-05-15 2015-11-18 Biolnvent Internat Ab Medicaments, uses and methods
ES2919749T3 (es) 2014-06-11 2022-07-28 Molecular Templates Inc Moléculas dirigidas a células citotóxicas resistentes a la escisión por proteasa
MX2017010072A (es) 2015-02-05 2017-11-09 Molecular Templates Inc Moleculas multivalentes que se enlazan a cd20, las cuales comprenden regiones efectoras de la subunidad a de la toxina shiga, y composiciones enriquecidas de las mismas.
JP6726676B2 (ja) * 2015-03-16 2020-07-22 ヘルムホルツ・ツェントルム・ミュンヒェン・ドイチェス・フォルシュンクスツェントルム・フューア・ゲズントハイト・ウント・ウムベルト（ゲーエムベーハー）Ｈｅｌｍｈｏｌｔｚ Ｚｅｎｔｒｕｍ Ｍｕｅｎｃｈｅｎ Ｄｅｕｔｓｃｈｅｓ Ｆｏｒｓｃｈｕｎｇｓｚｅｎｔｒｕｍ ｆｕｅｒ Ｇｅｓｕｎｄｈｅｉｔ ｕｎｄ Ｕｍｗｅｌｔ （ＧｍｂＨ） Ｈｂｖ感染および関連症状を治療するための三重特異的結合分子
AU2016271124C1 (en) 2015-05-30 2020-05-14 Molecular Templates, Inc. De-immunized, Shiga toxin a subunit scaffolds and cell-targeting molecules comprising the same
EP3389711A1 (en) 2015-12-18 2018-10-24 Novartis AG Antibodies targeting cd32b and methods of use thereof
WO2018106895A1 (en) 2016-12-07 2018-06-14 Molecular Templates, Inc. Shiga toxin a subunit effector polypeptides, shiga toxin effector scaffolds, and cell-targeting molecules for site-specific conjugation
US10610104B2 (en) 2016-12-07 2020-04-07 Progenity, Inc. Gastrointestinal tract detection methods, devices and systems
EP3573648B1 (en) 2017-01-25 2023-11-22 Molecular Templates, Inc. Cell-targeting molecules comprising de-immunized, shiga toxin a subunit effectors and cd8+ t-cell epitopes
CN110536699A (zh) * 2017-01-30 2019-12-03 俄亥俄州立创新基金会 被动抗体依赖性细胞介导的活化
US20210138213A1 (en) 2017-03-30 2021-05-13 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
WO2018229715A1 (en) 2017-06-16 2018-12-20 Novartis Ag Compositions comprising anti-cd32b antibodies and methods of use thereof
WO2018229706A1 (en) 2017-06-16 2018-12-20 Novartis Ag Combination therapy for the treatment of cancer
EP3700933A1 (en) 2017-10-25 2020-09-02 Novartis AG Antibodies targeting cd32b and methods of use thereof
BR112020010579A2 (pt) 2017-11-30 2020-11-10 Novartis Ag receptor de antígeno quimérico de alvejamento de bcma e usos do mesmo
AU2019257343A1 (en) 2018-04-17 2020-09-10 Molecular Templates, Inc. HER2-targeting molecules comprising de-immunized, Shiga toxin A Subunit scaffolds
CN108823211A (zh) * 2018-05-04 2018-11-16 中国医学科学院基础医学研究所 一种cd19核酸适配体及其应用
UY38251A (es) 2018-06-01 2019-12-31 Novartis Ag Moléculas de unión contra bcma y usos de las mismas
WO2019246312A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
US12227565B2 (en) 2018-06-20 2025-02-18 Biora Therapeutics, Inc. Method of formulating a pharmaceutical composition comprising administering an immune modulator to the small intestine
US20220249814A1 (en) 2018-11-19 2022-08-11 Progenity, Inc. Methods and devices for treating a disease with biotherapeutics
EP3999186A1 (en) * 2019-07-17 2022-05-25 BioInvent International AB Antibody combinations for treatment of cancer in specific patients
CN114945386A (zh) * 2019-10-18 2022-08-26 基因泰克公司 使用抗CD79b免疫缀合物治疗弥漫性大B细胞淋巴瘤的方法
CN121197633A (zh) 2019-12-13 2025-12-26 比特比德科有限责任公司 用于将治疗剂递送至胃肠道的可摄取装置
EP3919077A1 (en) 2020-06-04 2021-12-08 BioInvent International AB Model for prediction of tolerability issues in connection with intravenous administration of therapeutic antibodies
TW202210104A (zh) * 2020-06-04 2022-03-16 瑞典商生物創新國際有限公司 皮下抗體調配物
US20240025993A1 (en) 2020-11-06 2024-01-25 Novartis Ag Cd19 binding molecules and uses thereof
TW202336033A (zh) 2022-03-07 2023-09-16 瑞典商生物創新國際有限公司 抗體之新穎組合及用途
WO2023201339A1 (en) 2022-04-15 2023-10-19 Kyverna Therapeutics, Inc. Methods and compositions for treating autoimmune disease
US20240261405A1 (en) 2022-06-08 2024-08-08 Kyverna Therapeutics, Inc. Methods and compositions for treating autoimmune disease

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4880078A (en) 1987-06-29 1989-11-14 Honda Giken Kogyo Kabushiki Kaisha Exhaust muffler
WO1992019244A2 (en) 1991-05-01 1992-11-12 Henry M. Jackson Foundation For The Advancement Of Military Medicine A method for treating infectious respiratory diseases
US5934272A (en) 1993-01-29 1999-08-10 Aradigm Corporation Device and method of creating aerosolized mist of respiratory drug
US6019968A (en) 1995-04-14 2000-02-01 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
DK0885002T3 (da) 1996-03-04 2011-08-22 Penn State Res Found Materialer og fremgangsmåder til forøgelse af cellulær internalisering
US5855913A (en) 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
US5985309A (en) 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
DE69732306T2 (de) 1997-01-16 2006-01-12 Massachusetts Institute Of Technology, Cambridge Zubereitung von partikelhaltigen arzneimitteln zur inhalation
CA2336139C (en) 1998-06-24 2008-10-14 Advanced Inhalation Research, Inc. Large porous particles emitted from an inhaler
US6737056B1 (en) * 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
RU2305561C2 (ru) * 1999-11-08 2007-09-10 Байоджен Айдек Инк. Лечение в-клеточных злокачественных опухолей с использованием антител против cd40l в комбинации с антителами против cd20 и/или химиотерапией и лучевой терапией
EP1534335B9 (en) 2002-08-14 2016-01-13 Macrogenics, Inc. Fcgammariib-specific antibodies and methods of use thereof
US20060177439A1 (en) * 2004-12-15 2006-08-10 Scott Koenig FcgammaRIIB-specific antibodies and methods of use thereof
US20090010920A1 (en) 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
WO2005018669A1 (en) 2003-08-18 2005-03-03 Macrogenics, Inc. Fcϝriib-specific antibodies and methods of use thereof
AU2004293184B2 (en) 2003-11-26 2010-12-16 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Substance binding human IgG Fc receptor IIb
CN101001872A (zh) * 2004-04-16 2007-07-18 宏观基因有限公司 FcγRIIB－特异性抗体及其使用方法
SG173322A1 (en) * 2004-04-16 2011-08-29 Macrogenics Inc Dw Us Fc gammad riib - specific antibodies and methods of use thereof
WO2005110474A2 (en) * 2004-05-10 2005-11-24 Macrogenics, Inc. HUMANIZED FcϜRIIB SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF
AU2005300261A1 (en) * 2004-05-20 2006-05-11 Imperial College Innovations Limited IgE-retargeting, Function-Altering Molecules (ERFAM) for treatment of allergic diseases
EP1810035A4 (en) 2004-11-10 2010-03-17 Macrogenics Inc GENERATION OF FC ANTIBODY REGIONS FOR EFFECTOR FUNCTION
EP1674479A1 (en) * 2004-12-22 2006-06-28 Memorial Sloan-Kettering Cancer Center Modulation of Fc Gamma receptors for optimizing immunotherapy
WO2008002933A2 (en) 2006-06-26 2008-01-03 Macrogenics, Inc. Combination of fcgammariib antibodies and cd20-specific antibodies and methods of use thereof
WO2008140603A2 (en) 2006-12-08 2008-11-20 Macrogenics, Inc. METHODS FOR THE TREATMENT OF DISEASE USING IMMUNOGLOBULINS HAVING FC REGIONS WITH ALTERED AFFINITIES FOR FCγR ACTIVATING AND FCγR INHIBITING
US20120030144A1 (en) * 2007-11-08 2012-02-02 Pikamab, Inc. Methods for doing business using biomarkers
WO2009083009A2 (en) * 2008-01-03 2009-07-09 Genmab A/S Monoclonal antibodies against cd32b
WO2010080994A2 (en) 2009-01-08 2010-07-15 The Uab Research Foundation Process for regulating immune response
GB201013989D0 (en) * 2010-08-20 2010-10-06 Univ Southampton Biological materials and methods of using the same
GB2526139A (en) 2014-05-15 2015-11-18 Biolnvent Internat Ab Medicaments, uses and methods

Also Published As

Publication number Publication date
US20210346498A1 (en) 2021-11-11
EP2606068B1 (en) 2017-09-27
US10525129B2 (en) 2020-01-07
CN114099666B (zh) 2025-05-02
RU2017143633A3 (https=) 2021-01-29
ES2653685T3 (es) 2018-02-08
KR20140005866A (ko) 2014-01-15
NO2606068T3 (https=) 2018-02-24
CA2808744A1 (en) 2012-02-23
CN107670034B (zh) 2021-07-20
CN114099666A (zh) 2022-03-01
CN114099667B (zh) 2025-10-21
CN114099668A (zh) 2022-03-01
CN103080131A (zh) 2013-05-01
CN114099669A (zh) 2022-03-01
AU2011290503B2 (en) 2015-09-03
SI2606068T1 (en) 2018-01-31
RU2769949C2 (ru) 2022-04-11
US12527866B2 (en) 2026-01-20
CA2808744C (en) 2023-03-07
AU2011290503A1 (en) 2013-03-07
RU2013112345A (ru) 2014-09-27
JP6215704B2 (ja) 2017-10-18
PL2606068T3 (pl) 2018-03-30
JP6421140B2 (ja) 2018-11-07
CN107670034A (zh) 2018-02-09
RU2017143633A (ru) 2019-02-14
JP2016138129A (ja) 2016-08-04
KR101948609B1 (ko) 2019-02-15
PT2606068T (pt) 2017-12-29
JP2013537547A (ja) 2013-10-03
CN114099667A (zh) 2022-03-01
WO2012022985A1 (en) 2012-02-23
US20200069798A1 (en) 2020-03-05
US11623005B2 (en) 2023-04-11
HUE037478T2 (hu) 2018-08-28
CN121313820A (zh) 2026-01-13
CN114099702A (zh) 2022-03-01
US20130251706A1 (en) 2013-09-26
US20230381310A1 (en) 2023-11-30
CN114099702B (zh) 2024-08-27
CN114099668B (zh) 2025-10-17
EP2606068A1 (en) 2013-06-26
EP3263602A1 (en) 2018-01-03
DK2606068T3 (da) 2017-11-20

Similar Documents

Publication Publication Date Title
GB201013989D0 (en) Biological materials and methods of using the same
IL249669A0 (en) Converted 5-fluoro-1h-pyrazolopyridines and their use
GB201011771D0 (en) Biological material and particular uses thereof
SI2516468T1 (sl) Protitelesa proti flt3 in postopki uporabe istih
ZA201300612B (en) Novel bacteria and methods of use thereof
PT2539326T (pt) Ariltriazolonas ligadas a bisaril e sua utilização
LT2946791T (lt) Anti-cd277 antikūnai ir jų panaudojimas
ZA201107555B (en) Anti-17f antibodies and methods of use thereof
ZA201208173B (en) Peptices and their use
GB2477597B (en) Disinfectant materials and methods
GB0904825D0 (en) Biological materials and uses thereof
ZA201303773B (en) Compounds and their use
ZA201300174B (en) Anti-neuropilin antibodies and methods of use
EP2525651A4 (en) NEW CENTROMERE AND METHOD FOR THEIR USE
PT2406280E (pt) Materiais biológicos e utilizações dos mesmos
EP2649217A4 (en) ARTICLE AND METHOD FOR ITS MANUFACTURE AND USE
GB201020357D0 (en) Compounds and methods of making the same
GB0922143D0 (en) Biological materials and uses thereof
GB201009307D0 (en) Biological materials and uses thereof
GB201112000D0 (en) Biological materials and uses thereof
GB201011770D0 (en) Biological material and there uses thereof
GB201019361D0 (en) Biosensor and uses thereof
GB201000305D0 (en) Compounds and their use
GB201000308D0 (en) Compounds and their use
GB201000309D0 (en) Compounds and their use

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)